Department of Paediatric Endocrinology, Alder Hey Children's NHS Foundation Trust, Liverpool, UK.
Academic Endocrine Unit, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
J Clin Endocrinol Metab. 2020 May 1;105(5):1393-400. doi: 10.1210/clinem/dgaa111.
Familial hypocalciuric hypercalcemia type 1 (FHH1) is caused by loss-of-function mutations of the calcium-sensing receptor (CaSR) and is considered a benign condition associated with mild-to-moderate hypercalcemia. However, the children of parents with FHH1 can develop a variety of disorders of calcium homeostasis in infancy.
The objective of this work is to characterize the range of calcitropic phenotypes in the children of a mother with FHH1.
A 3-generation FHH kindred was assessed by clinical, biochemical, and mutational analysis following informed consent.
The FHH kindred comprised a hypercalcemic man and his daughter who had hypercalcemia and hypocalciuria, and her 4 children, 2 of whom had asymptomatic hypercalcemia, 1 was normocalcemic, and 1 suffered from transient neonatal hypocalcemia and seizures. The hypocalcemic infant had a serum calcium of 1.57 mmol/L (6.28 mg/dL); normal, 2.0 to 2.8 mmol/L (8.0-11.2 mg/dL) and parathyroid hormone of 2.2 pmol/L; normal 1.0 to 9.3 pmol/L, and required treatment with intravenous calcium gluconate infusions. A novel heterozygous p.Ser448Pro CaSR variant was identified in the hypercalcemic individuals, but not the children with hypocalcemia or normocalcemia. Three-dimensional modeling predicted the p.Ser448Pro variant to disrupt a hydrogen bond interaction within the CaSR extracellular domain. The variant Pro448 CaSR, when expressed in HEK293 cells, significantly impaired CaSR-mediated intracellular calcium mobilization and mitogen-activated protein kinase responses following stimulation with extracellular calcium, thereby demonstrating it to represent a loss-of-function mutation.
Thus, children of a mother with FHH1 can develop hypercalcemia or transient neonatal hypocalcemia, depending on the underlying inherited CaSR mutation, and require investigations for serum calcium and CaSR mutations in early childhood.
家族性低钙血症性高钙血症 1 型(FHH1)是由钙敏感受体(CaSR)的功能丧失突变引起的,被认为是一种与轻度至中度高钙血症相关的良性疾病。然而,FHH1 父母的孩子在婴儿期可能会出现多种钙稳态紊乱。
本研究旨在描述 FHH1 母亲的孩子中钙调节表型的范围。
在知情同意后,通过临床、生化和突变分析评估了一个 3 代 FHH 家族。
该 FHH 家族包括一名高钙血症男性及其女儿,他们均患有高钙血症和低钙尿症,其 4 名子女中,2 名无症状高钙血症,1 名血钙正常,1 名患有短暂性新生儿低钙血症和癫痫发作。低钙血症婴儿的血清钙为 1.57mmol/L(6.28mg/dL);正常值为 2.0-2.8mmol/L(8.0-11.2mg/dL),甲状旁腺激素为 2.2pmol/L;正常值为 1.0-9.3pmol/L,需要静脉输注葡萄糖酸钙治疗。在高钙血症个体中发现了一种新的杂合 p.Ser448Pro CaSR 变体,但在低钙血症或血钙正常的儿童中未发现。三维建模预测 p.Ser448Pro 变体破坏了 CaSR 细胞外域内的氢键相互作用。当表达在 HEK293 细胞中时,变体 Pro448 CaSR 显著损害了 CaSR 介导的细胞内钙动员和丝裂原活化蛋白激酶反应,这表明它代表了一种功能丧失突变。
因此,FHH1 母亲的孩子可能会出现高钙血症或短暂性新生儿低钙血症,具体取决于潜在的遗传性 CaSR 突变,并需要在幼儿期进行血清钙和 CaSR 突变的调查。